TR200607613A2 - Lipaz inhibitörü içeren farmasötik formülasyonlar - Google Patents

Lipaz inhibitörü içeren farmasötik formülasyonlar

Info

Publication number
TR200607613A2
TR200607613A2 TR2006/07613A TR200607613A TR200607613A2 TR 200607613 A2 TR200607613 A2 TR 200607613A2 TR 2006/07613 A TR2006/07613 A TR 2006/07613A TR 200607613 A TR200607613 A TR 200607613A TR 200607613 A2 TR200607613 A2 TR 200607613A2
Authority
TR
Turkey
Prior art keywords
pharmaceutical formulations
formulations containing
lipase inhibitors
containing lipase
orlistat
Prior art date
Application number
TR2006/07613A
Other languages
English (en)
Inventor
Uslu Abdullah
Original Assignee
NOBEL İLAÇ SAN.ve TiC.A.Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOBEL İLAÇ SAN.ve TiC.A.Ş. filed Critical NOBEL İLAÇ SAN.ve TiC.A.Ş.
Priority to TR2006/07613A priority Critical patent/TR200607613A2/tr
Priority to PCT/TR2007/000152 priority patent/WO2008082373A2/en
Publication of TR200607613A2 publication Critical patent/TR200607613A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bu buluş obesite tedavisinde kullanılan mide ve pankreas lipaz inhibitörü etkinliğine sahip orlistat'ı içeren oral yolla alınmaya uygun bir farmasötik dozaj formülasyonunu tarif etmektedir.
TR2006/07613A 2006-12-29 2006-12-29 Lipaz inhibitörü içeren farmasötik formülasyonlar TR200607613A2 (tr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2006/07613A TR200607613A2 (tr) 2006-12-29 2006-12-29 Lipaz inhibitörü içeren farmasötik formülasyonlar
PCT/TR2007/000152 WO2008082373A2 (en) 2006-12-29 2007-12-28 Pharmaceutical formulations comprising lipase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2006/07613A TR200607613A2 (tr) 2006-12-29 2006-12-29 Lipaz inhibitörü içeren farmasötik formülasyonlar

Publications (1)

Publication Number Publication Date
TR200607613A2 true TR200607613A2 (tr) 2008-07-21

Family

ID=39589103

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2006/07613A TR200607613A2 (tr) 2006-12-29 2006-12-29 Lipaz inhibitörü içeren farmasötik formülasyonlar

Country Status (2)

Country Link
TR (1) TR200607613A2 (tr)
WO (1) WO2008082373A2 (tr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0901602B8 (pt) * 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
MX342962B (es) * 2009-09-18 2016-06-07 Teva Pharmaceuticals Holdings Mexico S A De C V Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma.
CN114767634A (zh) * 2022-03-14 2022-07-22 大邦(湖南)生物制药有限公司 一种奥利司他微丸及其制备方法、奥利司他胶囊

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
WO2000009123A1 (en) * 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa

Also Published As

Publication number Publication date
WO2008082373A2 (en) 2008-07-10
WO2008082373A3 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
MA31874B1 (fr) Inhibiteurs de bêta-lactamases
EA201100544A1 (ru) Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
CY1113122T1 (el) Μορφες δοσολογιας ανθεκτικες σε παραβιαση
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
NO20020770D0 (no) Anvendelse av monoaminoksidaseinhibitorer for fremstilling av legemidler egnet for behandling av fedme
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
NO20073631L (no) Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel
NO20071806L (no) Tabletter med steds- og tidsregulert gastrointestinal frigivelse av aktiv bestanddel.
EP1951211A4 (en) TRANSDERMALE PREPARATIONS WITH HYDROPHOBIC NON-STEROIDAL INFLAMMATORY INHIBITORS
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
EP1781277A4 (en) COMBINATION PREPARATION
MX2007002898A (es) Tableta con liberacion gastrointestinal controlada en sitio y tiempo del ingrediente activo.
NO20080035L (no) Benzooksazol-2-on derivater som lipase og fosfolipaseinhibitorer
BRPI0411347A (pt) combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia
NO20080034L (no) Benzotiazol-2-on derivater som lipase og fosfolipaseinhibitorer
TW200600121A (en) Pharmaceutical dosage forms
TR200607613A2 (tr) Lipaz inhibitörü içeren farmasötik formülasyonlar